D W Fry - JoVE Visualize

Showing results (61-70 of 82) with videos related to

Pageof 9

Sort By:

Anti-Cancer Drug Design|August 1, 1994

Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activityD W Fry, A J Kraker, R C Connors, et al.

Advances in Enzyme Regulation|January 1, 1984

Biochemical pharmacology of the lipophilic antifolate, trimetrexateR C Jackson, D W Fry, T J Boritzki, et al.

Biochemical Pharmacology|April 1, 1985

Biochemical and antitumor activity of tiazofurin and its selenium analog (2-beta-D-ribofuranosyl-4-selenazolecarboxamide)T J Boritzki, D A Berry, J A Besserer, et al.

Cancer Research|September 1, 1991

In vivo and in vitro evaluation of the alkylating agent carmethizoleW L Elliott, D W Fry, W K Anderson, et al.

Advances in Enzyme Regulation|January 1, 1987

Biochemical pharmacology and experimental chemotherapy studies with guanine-7-oxide, a novel purine antibioticR C Jackson, T J Boritzki, J A Besserer, et al.

Biochemical Pharmacology|November 14, 1997

Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitorD W Fry, J M Nelson, V Slintak, et al.

Science (New York, N.Y.)|August 19, 1994

A specific inhibitor of the epidermal growth factor receptor tyrosine kinaseD W Fry, A J Kraker, A McMichael, et al.

Cancer Research|September 15, 2000

Inhibition of epidermal growth factor receptor tyrosine kinase fails to suppress adenoma formation in ApcMin mice but induces duodenal injuryS R Ritland, S J Gendler, L J Burgart, et al.

Journal of Medicinal Chemistry|January 5, 1996

Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptorA J Bridges, H Zhou, D R Cody, et al.

Journal of Medicinal Chemistry|April 26, 1996

Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptorG W Rewcastle, B D Palmer, A M Thompson, et al.

Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:

Pageof 9

Anti-Cancer Drug Design|August 1, 1994

Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activityD W Fry, A J Kraker, R C Connors, et al.

Advances in Enzyme Regulation|January 1, 1984

Biochemical pharmacology of the lipophilic antifolate, trimetrexateR C Jackson, D W Fry, T J Boritzki, et al.

Biochemical Pharmacology|April 1, 1985

Biochemical and antitumor activity of tiazofurin and its selenium analog (2-beta-D-ribofuranosyl-4-selenazolecarboxamide)T J Boritzki, D A Berry, J A Besserer, et al.

Cancer Research|September 1, 1991

In vivo and in vitro evaluation of the alkylating agent carmethizoleW L Elliott, D W Fry, W K Anderson, et al.

Advances in Enzyme Regulation|January 1, 1987

Biochemical pharmacology and experimental chemotherapy studies with guanine-7-oxide, a novel purine antibioticR C Jackson, T J Boritzki, J A Besserer, et al.

Biochemical Pharmacology|November 14, 1997

Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitorD W Fry, J M Nelson, V Slintak, et al.

Science (New York, N.Y.)|August 19, 1994

A specific inhibitor of the epidermal growth factor receptor tyrosine kinaseD W Fry, A J Kraker, A McMichael, et al.

Cancer Research|September 15, 2000

Inhibition of epidermal growth factor receptor tyrosine kinase fails to suppress adenoma formation in ApcMin mice but induces duodenal injuryS R Ritland, S J Gendler, L J Burgart, et al.

Journal of Medicinal Chemistry|January 5, 1996

Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptorA J Bridges, H Zhou, D R Cody, et al.

Journal of Medicinal Chemistry|April 26, 1996

Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptorG W Rewcastle, B D Palmer, A M Thompson, et al.

Pageof 9